Skip to main content

Revenues Down, Losses Up for Sequenom in Q1

NEW YORK, April 29 (GenomeWeb News) - Sequenom today reported dwindling revenues and increased losses for the first quarter.


Revenues totaled $5.1 million, down from $7.4 million during the same quarter last year. "We see the number of new account opportunities for high-throughput genotyping reaching saturation," said CFO Steve Zaniboni in a statement.


Sequenom's R&D expenses increased slightly, to $6 million, from $5.9 million during the year-ago quarter.


The company recorded a net loss of $9.9 million, or $.25 per share, up from $8.5 million, or $.22 per share, during the first quarter of 2003.


As of March 31, San Diego-based Sequenom had $59.5 million in cash, cash equivalents, short-term investments and restricted cash.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.